Vol 7, No 4 (2011)
Review paper
Published online: 2011-10-26
The treatment interfering with EGFR in prostate cancer patients
Onkol. Prak. Klin 2011;7(4):208-214.
Abstract
Treatment of advanced androgen-independent prostate cancer is disappointing, therefore a lot of attempts
have been made, including various targeted therapies. One of the molecular targets is epidermal growth
factor receptor (EGFR), which plays an important role in the progression of prostate cancer, especially in
high proliferation, inhibition of apoptosis, increase of cellular motility, angiogenesis, cancer cell division
and survival. In this manuscript, a comprehensive overview of the efficacy and safety of drugs interfering
with function of EGFR, in the treatment of androgen-independent prostate cancer, is provided.
Onkol. Prak. Klin. 2011; 7, 4: 208–214
Onkol. Prak. Klin. 2011; 7, 4: 208–214
Keywords: prostate cancerepidermal growth factor receptorEGFRmonoclonal antibodiessmall molecule kinase inhibitors